Specifically, several previous reports have shown that EGFR mutations can be detected in 35.1–44.0%, 3.9–10.0%, and 11.5–14.3% of patients with adenosquamous carcinoma, squamous cell carcinoma and large cell carcinoma, respectively23, 24, 25. This evidence concerns the gene EGFR and squamous cell carcinoma.